Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Clearmind Medicine Inc
(CSE:
CMND
)
N/A
UNCHANGED
Last Price
Updated: 3:54 PM EDT, Mar 14, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Clearmind Medicine Inc
< Previous
1
2
3
4
Next >
Israel-Based Clearmind Medicine Files Patent Applications for Three Unique Combinations of Future Psychedelic-Based Compounds
February 22, 2023
From
Clearmind Medicine Inc.
Via
GlobeNewswire
SciSparc and Clearmind Collaboration Strengthens IP Portfolio with Three Provisional Patent Applications in the US
February 15, 2023
From
SciSparc Ltd
Via
GlobeNewswire
Israel-Based Clearmind Medicine Strengthening IP Portfolio with Three Provisional Patent Applications in the US
February 15, 2023
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Israel-Based Clearmind Medicine to Present at The OurCrowd Global Investor Summit Sponsored by Greenberg Traurig Tel Aviv
February 14, 2023
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Israeli- Based Clearmind Medicine to Host Virtual Investor Conference on Psychedelics for Obesity
February 08, 2023
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Israeli Biotech Clearmind Medicine Announces Positive Pre-Clinical Results Treating Major Depression With a Novel Ketamine-Based Compound
January 31, 2023
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Hebrew University' Yissum and Israeli Biotech Clearmind Medicine’s Psychedelic-Derived Obesity Treatment Presented by Professor Joseph Tam, D.M.D., Ph.D. at Isranalytica 2023
January 25, 2023
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Israel-Based Clearmind Successfully Completed Two R&D Projects With The Hebrew University of Jerusalem’s Tech Transfer Company, Yissum
January 19, 2023
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Israel-Based Clearmind Announces Additional Positive Results from the Third Part of its Pre-Clinical Study for Cocaine Addiction Treatment
January 17, 2023
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Israel-Based Clearmind Medicine Successfully Completes Production of CMND-100 Drug Candidate for Clinical Trial
January 10, 2023
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Israel-Based Clearmind Medicine Shows Efficacy of Psychedelic- Derived Obesity Treatment in Pre-Clinical Trial
January 05, 2023
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Israel-Based Clearmind Medicine Inc. CEO Discusses the Potential of Psychedelics for Addiction Treatment in Audio Interview with SmallCapVoice.com
January 04, 2023
Via
ACCESSWIRE
Clearmind Medicine Inc.’s Psychedelic-Based Therapeutics Are Revolutionary To The Pharmaceutical Sector; Treating AUD In The Crosshairs ($CMND)
January 03, 2023
Via
AB Newswire
Topics
Intellectual Property
Exposures
Intellectual Property
Clearmind Medicine Inc. Positions To Deliver A First-To-Market Psychedelic-Based Treatment For AUD ($CMND)
December 29, 2022
Via
AB Newswire
Topics
Intellectual Property
Exposures
Intellectual Property
Product Safety
Clearmind Medicine Announces Shareholders Meeting Results
December 29, 2022
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Israel-Based Clearmind Medicine Announces First Clinical Center to Join Its Clinical Trial for Alcohol Use Disorder
December 28, 2022
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Clearmind Medicine Inc. Scores Milestone Patent Issuance To Expedite And Protect Psychedelic-Based Treatment For AUD ($CMND)
December 27, 2022
Via
AB Newswire
Topics
Intellectual Property
Exposures
Intellectual Property
Israel- Based Clearmind Medicine Granted U.S. Patent for Psychedelic-Based Alcohol Substitute
December 21, 2022
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Clearmind Medicine Inc. Is Disrupting The Pharmaceuticals Landscape; First-To-Market Psychedelic-Based Treatment For AUD In Its Crosshairs ($CMND)
December 21, 2022
Via
AB Newswire
Israeli Based Biotech Company Clearmind Medicine Inc’s CEO, Dr. Adi Zuloff-Shani, Issues Letter to Shareholders
December 15, 2022
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Israeli Based Biotech Company Clearmind Completes IND-Enabling Studies for CMND-100
December 13, 2022
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Israeli Biotech Clearmind Medicine Appoints ex-Red Bull Executive Special Advisor for Developing MEAI as Alcohol Substitute
December 09, 2022
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Clearmind Announces Initiation of CMND-100 Manufacturing Program to Address its Upcoming Clinical Trial
November 23, 2022
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Clearmind Medicine Announces Closing of US$7.5 Million Public Offering and Uplisting to the Nasdaq Capital Market
November 17, 2022
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Clearmind Medicine Announces Pricing of US$7.5 Million Public Offering and Uplisting to the Nasdaq Capital Market
November 14, 2022
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Clearmind Medicine Featured in "Psychedelics Tonight," Streaming on ALTRD.TV
October 11, 2022
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Rising Cases Of Mental Health Disorders of Stress, Anxiety & Addiction Fueling Need for Central Nervous System Therapeutics
June 07, 2022
Palm Beach, FL – June 7, 2022 – FinancialNewsMedia.com News Commentary – The global Central Nervous System (CNS) treatments and its market revenues had been steadily growing pre-pandemic and are still...
Via
FinancialNewsMedia
Exposures
COVID-19
Global Psychedelics Market Is Expected To Reach $8 Billion By 2029
May 24, 2022
Palm Beach, FL – May 24, 2022 – FinancialNewsMedia.com News Commentary – The Global psychedelic drugs market has been steadily rising for the past few years and is projected to continue at a faster...
Via
FinancialNewsMedia
InvestorNewsBreaks – Clearmind Medicine Inc. (CSE: CMND) (FSE: CWY0) (OTC: CMNDF) to Host Third Event in Psychedelics for Alcoholism Series
February 01, 2022
Via
Investor Brand Network
BioMedNewsBreaks – Clearmind Medicine Inc. (CSE: CMND) (OTC: CMNDF) (FSE: CWY0) Partners with Renowned Expert to Discuss Alcohol Use Disorder and Trauma at Upcoming Virtual Event
January 31, 2022
Via
Investor Brand Network
< Previous
1
2
3
4
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.